Skip to main content
. 2021 Aug 4;12:643282. doi: 10.3389/fimmu.2021.643282

Figure 2.

Figure 2

Establishment of the TP53/PIK3CA/ATM Mutation Classifier in BC Patients Treated with Immune Checkpoint Inhibitors. (A) OS status in the MSKCC ICI cohort. “Living” and “Deceased” patients were marked green and red, respectively. (B) Schematic diagram of the divisions based on risk scores. (C) Kaplan–Meier curves of overall survival in the MSKCC ICI cohort based on the TP53/PIK3CA/ATM mutation classifier. The median overall survival was 8.0 months (95% CI: 13.1–20.9 months) in the high-risk group, 13.0 months (95% CI: 7.8–18.2 months) in the moderate-risk group, and not reached in the low-risk group. (D) Forest plot for 215 patients who received ICI therapy. The vertical line represents the hazard ratio (HR) of 1.0. (E) Time-dependent ROC curves and AUCs at 3 years were used to assess the predictive accuracy of the classifier compared with TMB. AUC, area under the curve; BC, bladder cancer; CI, confidence interval; ICI, immune checkpoint inhibitors; MSKCC, Memorial Sloan Kettering Cancer Center; OS, overall survival; ROC, receiver operating characteristic; TMB, tumor mutation burden.